Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 57Carcinoma, Non-Small-Cell Lung 29Breast Neoplasms 18Rectal Neoplasms 14Ovarian Neoplasms 14Carcinoma, Hepatocellular 10Neoplasm Metastasis 9Glioblastoma 9Colonic Neoplasms 9Carcinoma, Renal Cell 8Uterine Cervical Neoplasms 7Fallopian Tube Neoplasms 7Brain Neoplasms 6Neoplasms 5Nasopharyngeal Carcinoma 5Lung Neoplasms 5Triple Negative Breast Neoplasms 4Recurrence 4Liver Neoplasms 4Inflammatory Breast Neoplasms 4Colorectal Cancer Metastatic 4Carcinoma, Ovarian Epithelial 4Stomach Neoplasms 3Pleural Effusion, Malignant 3Meningeal Carcinomatosis 3Melanoma 3Kidney Neoplasms 3Glioma 3Non-squamous Non-small Cell Lung Cancer 2Liver Metastasis Colon Cancer 2

Interventions

surufatinib 2regorafenib 2Oxaliplatin 2Irinotecan 2Fluorouracil 2Drug Therapy 2Bevacizumab 2raltitrexed 1nimotuzumab 1endostar protein 1aflibercept 1Folfox protocol 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Advanced Colorectal Cancer × Bevacizumab × Clear all
NCT02826837 2021-10-06

LEAC-102 for Advanced Colorectal Cancer

Taiwan Leader Biotech Corp.

Phase 1/2 Unknown
30 enrolled
Gastrointestinal

Advanced Colorectal Cancer

NCT03126071 2021-08-30

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Jiangsu Cancer Institute & Hospital

Phase 2 Unknown
100 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡